A survey evaluating the awareness of MRONJ within the Birmingham GMP community

A number of patients are routinely prescribed antiresorptive drugs that can be associated with developing medication‐related osteonecrosis of the jaw ( MRONJ ). When presenting to a dental setting, the majority are unaware of the small but relative risk of developing MRONJ . Prevention is currently the only evidence‐based method of reducing the incidence of MRONJ . Raising awareness of MRONJ could encourage GMP s to liaise with dental clinicians for premedication screening, preventative advice and specialist referrals. Methods An electronic survey consisting of 16 multiple‐choice questions, targeting GMP s and GMP trainees in Birmingham was conducted to evaluate their knowledge and awareness of MRONJ . A section for open comments was available. This was conducted between March and May 2016. Results 71% of the 49 participants surveyed, were aware of bisphosphonate‐related osteonecrosis of the jaw ( BRONJ ) and 6% were aware of the change in terminology to MRONJ . 56% of participants were aware of associated medications and 11% always mentioned the risk when prescribing relevant medications. 67% would not consider seeking a dental opinion prior to commencing these medications. 75% were unaware of the clinical presentation of MRONJ and 92% were unaware of associated guidelines. Encouragingly, 78% of the participants were interested in receiving further information and training. Conclusions This survey highlights the limited knowledge and training that GMP s and trainees in the West Midlands have regarding MRONJ . By raising awareness of this condition through leaflets and teaching, we can educate our colleagues and also encourage a more holistic management approach to this patient cohort.